GenMont Biotech Inc
GenMont Biotech Incorporation engages in the research and development, manufacture, and sale of various probiotic health products in Taiwan. It offers OEM and ODM services, including functional probiotic raw materials, capsules, powder, tablets, and liquid products. The company was founded in 2000 and is based in Tainan City, Taiwan.
Market Cap & Net Worth: GenMont Biotech Inc (3164)
GenMont Biotech Inc (TW:3164) has a market capitalization of $48.09 Million (NT$1.59 Billion) as of March 19, 2026. Listed on the TW stock exchange, this Taiwan-based company holds position #23422 globally and #1395 in its home market, demonstrating a 5.41% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying GenMont Biotech Inc's stock price NT$18.50 by its total outstanding shares 86010364 (86.01 Million).
GenMont Biotech Inc Market Cap History: 2015 to 2026
GenMont Biotech Inc's market capitalization history from 2015 to 2026. Data shows change from $53.78 Million to $48.09 Million (-0.89% CAGR).
GenMont Biotech Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how GenMont Biotech Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.14x
GenMont Biotech Inc's market cap is 0.14 times its annual revenue
1740.90x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.92x
GenMont Biotech Inc's market cap is 0.92 times its annual earnings
0.11x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $53.78 Million | $534.72 Million | -$98.03 Million | 0.10x | N/A |
| 2016 | $52.12 Million | $540.78 Million | -$235.94 Million | 0.10x | N/A |
| 2017 | $51.01 Million | $380.65 Million | $45.60 Million | 0.13x | 1.12x |
| 2018 | $59.21 Million | $406.53 Million | $158.02 Million | 0.15x | 0.37x |
| 2019 | $58.30 Million | $346.24 Million | $57.45 Million | 0.17x | 1.01x |
| 2020 | $54.11 Million | $325.19 Million | $60.88 Million | 0.17x | 0.89x |
| 2021 | $60.54 Million | $427.93 Million | $113.13 Million | 0.14x | 0.54x |
| 2022 | $61.61 Million | $368.55 Million | $56.98 Million | 0.17x | 1.08x |
| 2023 | $64.21 Million | $318.01 Million | $32.99 Million | 0.20x | 1.95x |
| 2024 | $52.51 Million | $385.37 Million | $57.25 Million | 0.14x | 0.92x |
Competitor Companies of 3164 by Market Capitalization
Companies near GenMont Biotech Inc in the global market cap rankings as of March 19, 2026.
Key companies related to GenMont Biotech Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
GenMont Biotech Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, GenMont Biotech Inc's market cap moved from $53.78 Million to $ 48.09 Million, with a yearly change of -0.89%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$48.09 Million | +0.82% |
| 2025 | NT$47.70 Million | -9.16% |
| 2024 | NT$52.51 Million | -18.22% |
| 2023 | NT$64.21 Million | +4.22% |
| 2022 | NT$61.61 Million | +1.77% |
| 2021 | NT$60.54 Million | +11.88% |
| 2020 | NT$54.11 Million | -7.19% |
| 2019 | NT$58.30 Million | -1.54% |
| 2018 | NT$59.21 Million | +16.09% |
| 2017 | NT$51.01 Million | -2.13% |
| 2016 | NT$52.12 Million | -3.09% |
| 2015 | NT$53.78 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of GenMont Biotech Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $48.09 Million USD |
| MoneyControl | $48.09 Million USD |
| MarketWatch | $48.09 Million USD |
| marketcap.company | $48.09 Million USD |
| Reuters | $48.09 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.